Table 2.
Baseline Characteristics (comparing patients who received second-line non-IO versus IO).
| Baseline Characteristics | Total | Non-IO | IO | p-Value |
|---|---|---|---|---|
| Number | 98 | 57 | 41 | - |
| Age (mean) | 61.9 | 61.6 | 62.3 | 0.76 |
| Gender (Female) | 21.4% | 17.5% | 26.8% | 0.26 |
| ECOG * (0–1) | 81.6% | 80.7% | 82.9% | 0.45 |
| Child Pugh > B7 | 16.3% | 17.5% | 14.6% | 0.15 |
| MELD ** score (mean) | 14.6 | 14.7 | 14.4 | 0.86 |
| AFP *** (mean) | 7982 | 10,951 | 3898 | 0.29 |
| Etiology of Liver Disease | ||||
| Hepatitis C | 56.1% | 57.9% | 53.7% | 0.67 |
| Hepatitis B | 6.1% | 5.3% | 7.3% | |
| Alcohol | 28.6% | 31.6% | 22.0% | |
| Other | 9.2% | 3.5% | 17.1% | |
| Previous Treatments | ||||
| Sorafenib | 87.8% | 98.2% | 73.2% | <0.01 |
| Surgery | 5.1% | 3.5% | 7.3% | 0.39 |
| Regional | 57.1% | 47.4% | 70.7% | 0.03 |
| Extrahepatic Metastasis | 22.4% | 17.5% | 29.3% | 0.73 |
* Eastern Cooperative Oncology Group (ECOG) performance status scores range from 0 to 5, with higher scores indicating greater disability. ** Model for End-Stage Liver Disease (MELD) is a predictor of survival for patients with advanced liver disease, with higher scores indicating higher mortality. *** Alpha-fetoprotein (AFP).